生脉散用于新型冠状病毒肺炎恢复期治疗的可行性探讨

Feasibility of Shengmai Powder in convalescent patients with novel coronavirus pneumonia

随着新型冠状病毒肺炎符合出院标准的患者逐日增多,恢复期的中医治疗应受到关注,国家卫生健康委员会及地方推出的诊疗方案中都加入了恢复期的中医辨证分型及治疗方药。查阅文献,并分析新冠肺炎恢复期的临床特征及中医分型,发现气阴两虚证为恢复期的主要证候,生脉散为气阴两虚证的代表方剂。对生脉散用于气阴两虚证疾病的临床应用及其抗肺纤维化和血管内皮细胞损伤的药理作用进行了综述,对其用于新冠肺炎恢复期的可行性进行探讨,以期为临床医生和患者的恢复期中医治疗提供参考。

As the number of discharged patients with novel coronavirus pneumonia(COVID-19)increased,TCM treatment received more attention.Some COVID-19 diagnosis and treatment plans issued by national health commission and local government recorded the syndrome differentiation and classification of TCM in the convalescent period and the treatment prescriptions.The clinical characteristics and TCM classification of convalescent period were also reported in recent literatures.Deficiency of Qi and Yin is the main syndrome in recovery period,and the Shengmai Powder(SMS)is the representative prescription.This paper reviews the studies of SMS in the treatment of deficiency of Qi and Yin,pulmonary fibrosis and vascular endothelial cell injury.The feasibility of SMS for the discharged patients with COVID-19 was discussed.This review will provide reference for clinical doctors and patients in the recovery period of TCM treatment.